TerrAscend: Real Cash Flow, Cheap Multiple, Re-Rating Still a Regulatory Bet

A cannabis producer announcing that it will sit for one-on-one meetings at an investor conference is about as routine as a corporate press release gets. TerrAscend, a multistate operator that trades on the TSX and the U.S. OTCQX board, issued exactly that note this week ahead of the ATB Cormark Capital Markets conference in New York on September 9, 2026. Read it as nothing more than an invitation to a meeting and you have read it correctly.

But it is worth reading as a signal of what the company is actually doing right now. TerrAscend is in the middle of a deliberate campaign to court institutional capital in preparation for a listing on a major U.S. exchange — management has said it is targeting the Nasdaq or the NYSE. Shareholders in August approved a share consolidation with 99.25% of votes in favor, which management called "an important milestone" on the path to that listing. A conference tour is the standard choreography of that effort, not new news.

The question it invites has nothing to do with the conference: has the operating business earned the audience it is asking for?

The operating story is thin growth with real cash

The June quarter is the honest version of "earned the audience." Net revenue was $67.1 million, up about 3% from a year earlier and 2% sequentially — a stable, low-growth business, not an accelerating one. Net revenue rose 3.3% year over year to $67.1 million.

The quality is better than the growth. Gross margin widened to 54.0%, up nearly three points year over year; adjusted EBITDA was $17.7 million, a 26% margin and an 11% gain on the year; and the company generated $7.4 million of operating cash flow and $5.7 million of free cash flow, its sixteenth straight quarter of positive operating cash flow. None of this is spectacular, but it is real, improving cash generation — a company pushing margins and cash conversion higher while revenue barely grows.

The counterweights sit on the balance sheet and in the income statement. TerrAscend still reports GAAP net losses, $10.1 million in the June quarter, and it carried roughly $206 million of total debt at the end of March against about $42 million of cash at mid-year. Net debt on the order of $165 million is a large sum relative to the business's size and, notably, close to the company's entire market value, which sits around $245 million.

How cheap is it, really?

This is where the market's skepticism shows up as a number rather than an opinion. Put the roughly $245 million market cap together with net debt of about $165 million and you get an enterprise value around $410 million. Against trailing adjusted EBITDA of roughly $70 million annualized, TerrAscend trades in the mid-single-digit EV/EBITDA range, and its free cash flow yield is close to 10%. By the raw multiples this is a cheap stock — cheaper, on the EBITDA basis, than the largest U.S. peers, some of which trade in the mid-teens.

Cheap multiples have to be explained, not just quoted. The reasons here are concrete: the debt load, low single-digit growth, persistent GAAP losses, and an OTC microcap that institutional investors have historically had trouble owning. The market is pricing TerrAscend at a discount for the federal legal overhang and for genuine doubt that a money-losing, slowly growing, heavily levered company will ever re-rate.

That skepticism is not automatically wrong. Cheap becomes a reason to buy only when the discount overstates real deterioration, or when a visible catalyst exists to close it. The deterioration here is not severe — cash flow is positive and improving — but the catalyst is the fragile part of the case.

The re-rating is a bet, and the clock is the proof

Everything that could justify a meaningfully higher multiple sits outside TerrAscend's reported economics. The U.S. listing is a pending process with no guaranteed timing. The regulatory tailwind is narrower than the initial celebration suggested: the Justice Department's final rule, effective April 28, 2026, moved medical and FDA-approved cannabis to Schedule III, but adult-use cannabis — the bulk of this industry — remains a Schedule I substance under federal law, and money-laundering exposure still hangs over the sector. Pennsylvania, where five of TerrAscend's six Apothecarium stores rank among the state's top 15 and a potential adult-use expansion would matter most, has not legalized; the prospects for adult-use legislation there were seen as fading as recently as early 2026.

So the honest reading is: a real, cheap, improving cash-flow business whose upside is gated behind corporate and regulatory events that have not happened yet. That is a "wait for proof" setup for most readers, not a forced buy — especially with net debt at roughly two-thirds of market value, and a management team that just raised more convertible capital, adding to the debt even as it lowered its interest cost and extended maturities to 2031.

The proof points are concrete and near-term. Whether TerrAscend actually files for and completes the U.S. listing, and what it gives up to get there; the third-quarter report in November, which should show whether revenue is holding at this modest growth while margins keep rising; and any movement in Harrisburg on adult use. The bull case only earns its keep if the operating quarter holds its footing while the regulatory ladder actually gets climbed. Until then, the stock is what it looks like: genuinely cheap on cash flows it is finally producing, with the payoff still hostage to steps it has yet to take.